Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, et al.
iScience (2020) Vol. 24, Iss. 1, pp. 101992-101992
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

One year update on the COVID-19 pandemic: Where are we now?
Sanjay Kumar Mishra, Timir Tripathi
Acta Tropica (2020) Vol. 214, pp. 105778-105778
Open Access | Times Cited: 186
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Dharma Rao Tompa, Aruldoss Immanuel, Srimari Srikanth, et al.
International Journal of Biological Macromolecules (2021) Vol. 172, pp. 524-541
Open Access | Times Cited: 184
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
Agnieszka M. Szemiel, Andres Merits, Richard Orton, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 9, pp. e1009929-e1009929
Open Access | Times Cited: 138
Molnupiravir: A new candidate for COVID‐19 treatment
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee
Pharmacology Research & Perspectives (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 110
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study
Chiara Sepulcri, Chiara Dentone, Małgorzata Mikulska, et al.
Open Forum Infectious Diseases (2021) Vol. 8, Iss. 11
Open Access | Times Cited: 85
SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation
Gang Xu, Ying Li, Shengyuan Zhang, et al.
Cell Research (2021) Vol. 31, Iss. 12, pp. 1230-1243
Open Access | Times Cited: 84
Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies
Amal Mahmoud, Ahmed Mostafa, Ahmed A. Al‐Karmalawy, et al.
Heliyon (2021) Vol. 7, Iss. 9, pp. e07962-e07962
Open Access | Times Cited: 78
Accelerating COVID-19 Research Using Molecular Dynamics Simulation
Aditya K. Padhi, Soumya Lipsa Rath, Timir Tripathi
The Journal of Physical Chemistry B (2021) Vol. 125, Iss. 32, pp. 9078-9091
Closed Access | Times Cited: 66
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Chemical Reviews (2022) Vol. 122, Iss. 13, pp. 11287-11368
Open Access | Times Cited: 58
Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach
Taj Mohammad, Arunabh Choudhury, Insan Habib, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 58
Review on molnupiravir as a promising oral drug for the treatment of COVID-19
Elham Zarenezhad, Mahrokh Marzi
Medicinal Chemistry Research (2022) Vol. 31, Iss. 2, pp. 232-243
Open Access | Times Cited: 49
Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions
Anant Narayan Bhatt, Abhishek Kumar, Yogesh Rai, et al.
Life Sciences (2022) Vol. 295, pp. 120411-120411
Open Access | Times Cited: 45
Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations
Aditya K. Padhi, Aniruddha Seal, Javed Masood Khan, et al.
European Journal of Pharmacology (2020) Vol. 894, pp. 173836-173836
Open Access | Times Cited: 65
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
Ying Li Weng, Shiv Rakesh Naik, Nadia Dingelstad, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 49
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma
Current Opinion in Pharmacology (2021) Vol. 62, pp. 64-73
Open Access | Times Cited: 43
Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes
Aditya K. Padhi, Timir Tripathi
Biochemical and Biophysical Research Communications (2022) Vol. 629, pp. 54-60
Open Access | Times Cited: 35
A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19
Stephen A. Chitty, Sarah Mobbs, Brian S. Rifkin, et al.
Critical Care Explorations (2022) Vol. 4, Iss. 4, pp. e0662-e0662
Open Access | Times Cited: 33
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, et al.
Pharmacological Research (2022) Vol. 179, pp. 106201-106201
Open Access | Times Cited: 29
The impact of remdesivir on SARS-CoV-2 evolution in vivo
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, et al.
JCI Insight (2025)
Open Access
Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
Ahmed A. Al‐Karmalawy, Raya Soltane, Ayman Abo Elmaaty, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1317-1317
Open Access | Times Cited: 39
DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CLpro) of SARS-CoV-2
Pooja Yadav, Meenakshi Rana, Papia Chowdhury
Journal of Molecular Structure (2021) Vol. 1246, pp. 131253-131253
Open Access | Times Cited: 38
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges
Xiao‐Ying Xu, Yuheng Chen, Xinyu Lu, et al.
Biochemical Pharmacology (2022) Vol. 205, pp. 115279-115279
Open Access | Times Cited: 22
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Fatma Haddad, Ghadeer Dokmak, Rafik Karaman
Life (2022) Vol. 12, Iss. 11, pp. 1758-1758
Open Access | Times Cited: 22
Computational Protein Design for COVID-19 Research and Emerging Therapeutics
Parismita Kalita, Timir Tripathi, Aditya K. Padhi
ACS Central Science (2023) Vol. 9, Iss. 4, pp. 602-613
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top